AYTU — Aytu BioPharma, Inc.

Summary of AYTU Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $15.2 million, down from $16.2 million year-over-year.
  • ADHD Portfolio: $13.2 million, slightly down from $13.8 million year-over-year and flat compared to Q1 2026.
  • Pediatric Portfolio: $1.7 million, up from $715,000 in Q1 but down from $2.7 million year-over-year.
• Gross Margin: 63.5%, down from 66.5% year-over-year, primarily due to decreased net revenue and transition-related expenses.
• Operating Expenses: $11.1 million, up from $10.2 million year-over-year, driven by increased investments in the ExuA launch.
• Net Loss: $10.6 million, or $1.05 per share, compared to a net income of $800,000, or $0.13 per share, in the prior year.
• Adjusted EBITDA: Negative $800,000, down from positive $1.3 million year-over-year.
• Cash Position: $30 million as of December 31, 2025, compared to $32.6 million at the end of Q1 2026.

2. Strategic Updates and Business Highlights

• Launch of ExuA: The first FDA-approved 5-HT1A agonist for major depressive disorder (MDD) was commercially launched, with a focus on prescriber adoption and brand growth.
• Sales Strategy: A highly motivated sales team is supported by a virtual sales force and targeted promotional strategies to maximize impact.
• Patient Access: The RxConnect platform aims to streamline patient access, guaranteeing predictable coverage and minimizing out-of-pocket costs for commercially insured patients.
• Early Performance: Over 100 doctors have prescribed ExuA, with positive early feedback from patients regarding tolerability and satisfaction.

3. Forward Guidance and Outlook

• ExuA Revenue Expectations: Initial ramp-up in net revenue is anticipated to be gradual, with scripts expected to grow ahead of recognized revenue due to promotional strategies.
• Cash Breakeven: Expected at approximately $16.6 million per quarter, with a projected quarterly normalized run rate of about $11.6 million by the end of the fiscal year.
• Salesforce Expansion: Expansion is unlikely in fiscal 2026 until cash flow supports it, with a focus on profitability before any growth in sales personnel.

4. Bad News, Challenges, or Points of Concern

• Declining Revenue: Overall net revenue decreased compared to the previous year, with specific declines in both ADHD and pediatric portfolios.
• Increased Net Loss: Significant losses attributed to derivative warrant liabilities and increased operating expenses related to the ExuA launch.
• Weather Impact: Severe weather conditions affected prescription fill rates and sales representative productivity, potentially hindering early launch momentum.
• Generic Competition: The introduction of generic competition for ADHD products may impact future revenue, although the company believes its RxConnect platform will mitigate some of these effects.

5. Notable Q&A Insights

• Physician Feedback: Early prescribers of ExuA are motivated by the drug's mechanism of action and the need for alternatives due to side effects from existing treatments.
• Direct-to-Consumer Campaign: Plans include web-based strategies focusing on search engine optimization and social media, while being cautious of FDA regulations.
• Supply Chain Readiness: The company has adequate supply to meet demand and has resolved initial distribution delays caused by weather.

Overall, AYTU is at a pivotal moment with the launch of ExuA, facing challenges related to revenue declines and market competition but optimistic about the drug's potential and early feedback from prescribers and patients.